Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM.

Clin Cancer Res. 2018 Jan 1;24(1):189-196. doi: 10.1158/1078-0432.CCR-17-1767. Epub 2017 Oct 2.

PMID:
28972044
2.

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo AS, Furman WL.

Clin Cancer Res. 2017 Nov 1;23(21):6441-6449. doi: 10.1158/1078-0432.CCR-17-0379. Epub 2017 Sep 22.

PMID:
28939747
3.

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM.

Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017.

4.

FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.

Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Mier JW, Panka DJ, McDermott DF, Sondel PM.

Clin Cancer Res. 2017 May 1;23(9):2159-2168. doi: 10.1158/1078-0432.CCR-16-1874. Epub 2016 Oct 14.

PMID:
27742794
5.

Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Wang W, Erbe AK, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM.

Cancer Immunol Immunother. 2016 Dec;65(12):1523-1532. Epub 2016 Sep 30.

6.

Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Wang W, Erbe AK, Alderson KA, Phillips E, Gallenberger M, Gan J, Campana D, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2016 Sep;65(9):1047-59. doi: 10.1007/s00262-016-1864-z. Epub 2016 Jul 8.

7.

Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma.

Albertini MR, Ranheim EA, Zuleger CL, Sondel PM, Hank JA, Bridges A, Newton MA, McFarland T, Collins J, Clements E, Henry MB, Neuman HB, Weber S, Whalen G, Galili U.

Cancer Immunol Immunother. 2016 Aug;65(8):897-907. doi: 10.1007/s00262-016-1846-1. Epub 2016 May 20.

8.

In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Morris ZS, Guy EI, Francis DM, Gressett MM, Werner LR, Carmichael LL, Yang RK, Armstrong EA, Huang S, Navid F, Gillies SD, Korman A, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM.

Cancer Res. 2016 Jul 1;76(13):3929-41. doi: 10.1158/0008-5472.CAN-15-2644. Epub 2016 May 6.

9.

Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells.

Erbe AK, Wang W, Gallenberger M, Hank JA, Sondel PM.

Methods Mol Biol. 2016;1441:43-56. doi: 10.1007/978-1-4939-3684-7_4.

10.

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM.

Front Immunol. 2015 Jul 27;6:368. doi: 10.3389/fimmu.2015.00368. eCollection 2015. Review.

11.

NK cell-based immunotherapies in Pediatric Oncology.

McDowell KA, Hank JA, DeSantes KB, Capitini CM, Otto M, Sondel PM.

J Pediatr Hematol Oncol. 2015 Mar;37(2):79-93. doi: 10.1097/MPH.0000000000000303. Review.

12.

Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells.

Sheridan RT, Hudon J, Hank JA, Sondel PM, Kiessling LL.

Chembiochem. 2014 Jul 7;15(10):1393-8. doi: 10.1002/cbic.201402019. Epub 2014 Jun 6.

13.

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, Goldberg J, Hank JA, Billups CA, Wu J, Furman WL, McGregor LM, Otto M, Gillies SD, Handgretinger R, Santana VM.

J Clin Oncol. 2014 May 10;32(14):1445-52. doi: 10.1200/JCO.2013.50.4423. Epub 2014 Apr 7.

14.

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. doi: 10.1007/s00262-013-1430-x. Epub 2013 May 10.

15.

Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

J Immunol. 2012 Sep 1;189(5):2656-64. doi: 10.4049/jimmunol.1200934. Epub 2012 Jul 27.

16.

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.

Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2012 Dec;61(12):2261-71. doi: 10.1007/s00262-012-1286-5. Epub 2012 Jun 8.

17.

Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.

Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, Hank JA, Sondel PM.

Front Pharmacol. 2012 May 16;3:91. doi: 10.3389/fphar.2012.00091. eCollection 2012.

18.

Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.

Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM.

Int Immunopharmacol. 2011 Nov;11(11):1877-86. doi: 10.1016/j.intimp.2011.07.019. Epub 2011 Aug 18.

19.

Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J.

Cancer Immunol Immunother. 2011 Dec;60(12):1789-800. doi: 10.1007/s00262-011-1072-9. Epub 2011 Jul 27.

20.

Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.

Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, Gerbing RB, Sondel PM.

Pediatr Blood Cancer. 2011 Sep;57(3):398-405. doi: 10.1002/pbc.22966. Epub 2011 Jun 16.

21.

StrataGraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: results from a prospective, randomized, controlled dose escalation trial.

Centanni JM, Straseski JA, Wicks A, Hank JA, Rasmussen CA, Lokuta MA, Schurr MJ, Foster KN, Faucher LD, Caruso DM, Comer AR, Allen-Hoffmann BL.

Ann Surg. 2011 Apr;253(4):672-83. doi: 10.1097/SLA.0b013e318210f3bd.

22.

The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model.

Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2011 May;60(5):731-8. doi: 10.1007/s00262-011-0971-0. Epub 2011 Feb 22.

23.

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.

Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM.

J Leukoc Biol. 2011 Apr;89(4):625-38. doi: 10.1189/jlb.0710422. Epub 2011 Jan 19.

24.

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM.

Cancer Res. 2010 Dec 1;70(23):9554-61. doi: 10.1158/0008-5472.CAN-10-2211. Epub 2010 Oct 8.

25.

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM.

J Clin Oncol. 2010 Nov 20;28(33):4969-75. doi: 10.1200/JCO.2009.27.8861. Epub 2010 Oct 4.

26.

Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.

Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM.

Clin Cancer Res. 2009 Sep 15;15(18):5923-30. doi: 10.1158/1078-0432.CCR-08-2963. Epub 2009 Sep 8.

27.

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.

Yamane BH, Hank JA, Albertini MR, Sondel PM.

Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000. doi: 10.1517/13543780903048911. Review.

28.

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.

Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM.

J Clin Oncol. 2009 Jan 1;27(1):85-91. doi: 10.1200/JCO.2006.10.3564. Epub 2008 Dec 1.

29.

Intratumoral immunocytokine treatment results in enhanced antitumor effects.

Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2008 Dec;57(12):1891-902. doi: 10.1007/s00262-008-0519-0. Epub 2008 Apr 26.

30.

A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients.

Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, Hank JA, Mahvi DM, Albertini MR.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):540-9.

31.

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM; Children's Oncology Group.

Clin Cancer Res. 2006 Mar 15;12(6):1750-9.

32.

Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.

Choi BS, Sondel PM, Hank JA, Schalch H, Gan J, King DM, Kendra K, Mahvi D, Lee LY, Kim K, Albertini MR.

Cancer Immunol Immunother. 2006 Jul;55(7):761-74. Epub 2005 Sep 27.

PMID:
16187086
33.

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Albertini MR, Hank JA, Sondel PM.

Cancer Chemother Biol Response Modif. 2005;22:789-97. Review. No abstract available.

PMID:
16110641
34.

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.

King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P.

J Clin Oncol. 2004 Nov 15;22(22):4463-73. Epub 2004 Oct 13.

35.

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.

Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM.

Clin Cancer Res. 2004 Jul 15;10(14):4839-47.

36.

NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2004 Jan;53(1):41-52. Epub 2003 Sep 18.

PMID:
14504825
37.

Preclinical and clinical development of immunocytokines.

Sondel PM, Hank JA, Gan J, Neal Z, Albertini MR.

Curr Opin Investig Drugs. 2003 Jun;4(6):696-700. Review.

PMID:
12901228
38.

Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study.

Imboden M, Shi F, Pugh TD, Freud AG, Thom NJ, Hank JA, Hao Z, Staelin ST, Sondel PM, Mahvi DM.

Hum Gene Ther. 2003 Jul 20;14(11):1037-48.

PMID:
12885344
39.

Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine.

Hank JA, Surfus JE, Gan J, Ostendorf A, Gillies SD, Sondel PM.

Methods Mol Med. 2003;85:123-31. Review. No abstract available.

PMID:
12710203
40.

Antibody-directed, effector cell-mediated tumor destruction.

Sondel PM, Hank JA.

Hematol Oncol Clin North Am. 2001 Aug;15(4):703-21. Review.

PMID:
11676280
41.

Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease.

Hank JA, Albertini MR, Sondel PM.

Cancer Chemother Biol Response Modif. 1999;18:210-22. Review. No abstract available.

PMID:
10800484
42.

A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis.

Hotton KM, Khorsand M, Hank JA, Albertini M, Kim KM, Wilding G, Salamat MS, Larson M, Sondel P, Schiller JH.

Cancer. 2000 Apr 15;88(8):1892-901.

PMID:
10760767
43.

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.

Kendra K, Gan J, Ricci M, Surfus J, Shaker A, Super M, Frost JD, Rakhmilevich A, Hank JA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 1999 Aug;48(5):219-29.

PMID:
10478638
44.

Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.

Gan J, Kendra K, Ricci M, Hank JA, Gillies SD, Sondel PM.

Clin Diagn Lab Immunol. 1999 Mar;6(2):236-42.

45.

Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.

Hank JA, Surfus J, Gan J, Albertini M, Lindstrom M, Schiller JH, Hotton KM, Khorsand M, Sondel PM.

Clin Cancer Res. 1999 Feb;5(2):281-9.

46.

Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy.

Nicolet CM, Surfus JM, Hank JA, Sondel PM.

Cancer Immunol Immunother. 1998 Aug;46(6):327-37.

PMID:
9756417
47.
48.

Combination therapy with interleukin-2 and antitumor monoclonal antibodies.

Sondel PM, Hank JA.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7. Review.

PMID:
9457407
49.

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.

Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Storer B, Reisfeld RA, Sondel PM.

Clin Cancer Res. 1997 Aug;3(8):1277-88.

50.

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.

Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM.

Cancer. 1997 Jul 15;80(2):317-33.

PMID:
9217046

Supplemental Content

Support Center